Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease

American Journal of Pathology

Volumn 181, Issue 5, 2012, Pages 1672-1680

  Zerr, Pawel ^a   Distler, Alfiya ^a   Palumbo Zerr, Katrin ^a   Tomcik, Michal ^a,b   Vollath, Stefan ^a   Dees, Clara ^a   Egberts, Friederike ^c   Tinazzi, Ilaria ^d   Del Galdo, Francesco ^d   Distler, Oliver ^e   Schett, Georg ^a   Spriewald, Bernd M ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; COLLAGEN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE;

ADULT; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; SKIN ULCER; SKINFOLD THICKNESS; WEIGHT REDUCTION;

ANIMALS; CHRONIC DISEASE; DERMIS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84868133047     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.07.017     Document Type: Article

References (37)

1. F. Baron, R. Storb Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review Springer Semin Immunopathol 26 2004 71 94 (Pubitemid 40021958)
2. J.L. Ferrara, J.E. Levine, P. Reddy, E. Holler Graft-versus-host disease Lancet 373 2009 1550 1561
3. K. Baird, S.Z. Pavletic Chronic graft versus host disease Curr Opin Hematol 13 2006 426 435 (Pubitemid 44607443)
4. F.J. Clark, L. Freeman, A. Dzionek, J. Schmitz, D. McMullan, P. Simpson, J. Mason, P. Mahendra, C. Craddock, M. Griffiths, P.A. Moss, R. Chakraverty Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease Transplantation 75 2003 221 225 (Pubitemid 36139676)
5. F.J. Clark, R. Gregg, K. Piper, D. Dunnion, L. Freeman, M. Griffiths, G. Begum, P. Mahendra, C. Craddock, P. Moss, R. Chakraverty Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells Blood 103 2004 2410 2416 (Pubitemid 38326268)
6. L.E. French, T. Alcindor, M. Shapiro, K.S. McGinnis, D.J. Margolis, D. Porter, D.G. Leonard, A.H. Rook, F. Foss Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis Bone Marrow Transplant 30 2002 509 515 (Pubitemid 35331717)
7. K. Nakamura, R. Amakawa, M. Takebayashi, Y. Son, M. Miyaji, K. Tajima, K. Nakai, T. Ito, N. Matsumoto, K. Zen, Y. Kishimoto, S. Fukuhara IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD Bone Marrow Transplant 36 2005 639 647 (Pubitemid 43115021)
8. N. Namba, K. Shinagawa, N. Fujii, Y. Maeda, F. Ishimaru, K. Ikeda, T. Matsui, M. Tanimoto, Y. Katayama Predominant infiltration of monocytes in chronic graft-versus-host disease Transplantation 83 2007 220 224 (Pubitemid 46185213)
9. A. Saxon, R.E. McIntyre, R.H. Stevens, R.P. Gale Lymphocyte dysfunction in chronic graft-versus-host disease Blood 58 1981 746 751 (Pubitemid 11015831)
10. S. Svegliati, A. Olivieri, N. Campelli, M. Luchetti, A. Poloni, S. Trappolini, G. Moroncini, A. Bacigalupo, P. Leoni, E.V. Avvedimento, A. Gabrielli Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease Blood 110 2007 237 241 (Pubitemid 47026840)
11. A. Wechalekar, T. Cranfield, D. Sinclair, M. Ganzckowski Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation Clin Lab Haematol 27 2005 247 249 (Pubitemid 41113497)
12. K. Yamashita, U. Choi, P.C. Woltz, S.F. Foster, M.C. Sneller, F.T. Hakim, D.H. Fowler, M.R. Bishop, S.Z. Pavletic, M. Tamari, K. Castro, A.J. Barrett, R.W. Childs, G.G. Illei, S.F. Leitman, H.L. Malech, M.E. Horwitz Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells Blood 103 2004 3986 3988 (Pubitemid 38596324)
13. S.R. Hymes, M.L. Turner, R.E. Champlin, D.R. Couriel Cutaneous manifestations of chronic graft-versus-host disease Biol Blood Marrow Transplant 12 2006 1101 1113 (Pubitemid 44660866)
14. H.M. Shulman, D. Kleiner, S.J. Lee, T. Morton, S.Z. Pavletic, E. Farmer, J.M. Moresi, J. Greenson, A. Janin, P.J. Martin, G. McDonald, M.E. Flowers, M. Turner, J. Atkinson, J. Lefkowitch, M.K. Washington, V.G. Prieto, S.K. Kim, Z. Argenyi, A.H. Diwan, A. Rashid, K. Hiatt, D. Couriel, K. Schultz, S. Hymes, G.B. Vogelsang Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Pathology Working Group Report Biol Blood Marrow Transplant 12 2006 31 47 (Pubitemid 43034096)
15. W.A. D'Angelo, J.F. Fries, A.T. Masi, L.E. Shulman Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls Am J Med 46 1969 428 440
16. B. White Immunopathogenesis of systemic sclerosis Rheum Dis Clin North Am 22 1996 695 708 (Pubitemid 26396046)
17. J.H. Distler, A. Jüngel, L.C. Huber, U. Schulze-Horsel, J. Zwerina, R.E. Gay, B.A. Michel, T. Hauser, G. Schett, S. Gay, O. Distler Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 2007 311 322 (Pubitemid 46106205)
18. L. Magro, M. Mohty, B. Catteau, V. Coiteux, P. Chevallier, L. Terriou, J.P. Jouet, I. Yakoub-Agha Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Blood 114 2009 719 722
19. A. Olivieri, F. Locatelli, M. Zecca, A. Sanna, M. Cimminiello, R. Raimondi, G. Gini, N. Mordini, A. Balduzzi, P. Leoni, A. Gabrielli, A. Bacigalupo Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 114 2009 709 718
20. G.L. Chen, S. Arai, M.E. Flowers, J.M. Otani, J. Qiu, E.C. Cheng, A. McMillan, L.J. Johnston, J.A. Shizuru, D.B. Miklos A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies Blood 118 2011 4070 4078
21. A. Akhmetshina, C. Dees, N. Busch, J. Beer, K. Sarter, J. Zwerina, A. Zimmer, O. Distler, G. Schett, J.H. Distler The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis Arthritis Rheum 60 2009 1129 1136
22. J. Kim, H.J. Kim, K. Park, J. Kim, H.-J. Choi, H. Yagita, S.H. Nam, H.R. Cho, B. Kwon Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease Blood 110 2007 776 782 (Pubitemid 47105417)
23. B.D. Jaffee, H.N. Claman Chronic graft-versus-host disease (GVHD) as a model for scleroderma, I: Description of model systems Cell Immunol 77 1983 1 12 (Pubitemid 13135593)
24. B.E. Anderson, J.M. McNiff, C. Matte, I. Athanasiadis, W.D. Shlomchik, M.J. Shlomchik Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease Blood 104 2004 1565 1573 (Pubitemid 39166539)
25. A. Akhmetshina, P. Venalis, C. Dees, N. Busch, J. Zwerina, G. Schett, O. Distler, J.H. Distler Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum 60 2009 219 224
26. J.F. Woessner Jr The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid Arch Biochem Biophys 93 1961 440 447
27. L. Claesson-Welsh Platelet-derived growth factor receptor signals J Biol Chem 269 1994 32023 32026
28. K. Dorey, J.R. Engen, J. Kretzschmar, M. Wilm, G. Neubauer, T. Schindler, G. Superti-Furga Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase Oncogene 20 2001 8075 8084 (Pubitemid 34030578)
29. R. Plattner, L. Kadlec, K.A. DeMali, A. Kazlauskas, A.M. Pendergast c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF Genes Dev 13 1999 2400 2411 (Pubitemid 29453611)
30. J.Y. Blay, M. von Mehren Nilotinib: a novel, selective tyrosine kinase inhibitor Semin Oncol 38 Suppl 1 2011 S3 S9
31. J.H. Distler, O. Distler Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies Ann Rheum Dis 69 Suppl 1 2010 i48 i51
32. T. O'Hare, D.K. Walters, M.W. Deininger, B.J. Druker AMN107: tightening the grip of imatinib Cancer Cell 7 2005 117 119 (Pubitemid 40248337)
33. X. An, A.K. Tiwari, Y. Sun, P.R. Ding, C.R. Ashby Jr, Z.S. Chen BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review Leuk Res 34 2010 1255 1268
34. E. Jabbour, H. Kantarjian, J. Cortes Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one Semin Hematol 47 2010 344 353
35. M. Koren-Michowitz, P. le Coutre, J. Duyster, C. Scheid, P. Panayiotidis, W. Prejzner, J.M. Rowe, M. Schwarz, N. Goldschmidt, A. Nagler Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant [published correction appears in Cancer 2011, 117:230] Cancer 116 2010 4564 4572
36. B.N. Kahner, R.T. Dorsam, S.R. Mada, S. Kim, T.J. Stalker, L.F. Brass, J.L. Daniel, D. Kitamura, S.P. Kunapuli Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation Blood 110 2007 2449 2456 (Pubitemid 47523166)
37. P. Kaur, N. Feldhahn, B. Zhang, D. Trageser, M. Müschen, V. Pertz, J. Groffen, N. Heisterkamp Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia Mol Cancer 6 2007 67